Skip to main content

Table 3 Factors associated with the decision to prescribe VDZ + BUD

From: Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study

Univariate logistic regression model

Odds ratio (95% CI)

p-value (for category)

p-value (for variable)

Sex (ref = Male)

Female

1.55 (0.74, 3.24)

-

0.2447

Age (ref = > 75 years old)

< 30 years old

1.78 (0.15, 20.86)

0.6470

 

30–49 years old

0.97 (0.08, 11.57)

0.9779

50–75 years old

1.47 (0.12, 18.29)

0.7661

Weight (ref = < 60 kg)

60–74 kg

0.31 (0.11, 0.89)

0.0288

 

> 74 kg

0.56 (0.20, 1.52)

0.2530

Smoking status (ref = Non-smoker)

Former smoker

0.97 (0.35, 2.74)

0.9575

 

Current smoker

1.02 (0.45, 2.31)

0.9726

Site location (ref = Belgium)

Switzerland

1.63 (0.63, 4.26)

0.3147

 

Israel

0.54 (0.16, 1.83)

0.3234

Charlson Comorbidity Index

 

0.92 (0.71, 1.19)

-

0.5185

Number of prior biologics received (ref = 0)

1

0.40 (0.16, 0.98)

0.0455

 

> 1

1.56 (0.55, 4.41)

0.4064

AP (ref = None)

Mild

1.75 (0.13, 23.67)

0.6743

 

Moderate

5.28 (0.62, 44.61)

0.1266

Severe

9.79 (0.90, 106.68)

0.0612

LSF

Number

0.95 (0.84, 1.07)

-

0.3948

AP/LSF score

Number

0.98 (0.87, 1.10)

-

0.7062

Phenotype (ref = Non-stricturing, non-penetrating)

Penetrating

0.41 (0.08, 2.11)

0.2858

 

Stricturing

1.43 (0.57, 3.62)

0.4461

Location of CD (ref = Ileum)

Colonic

0.96 (0.33, 2.79)

0.9323

 

Ileocolonic

1.75 (0.71, 4.32)

0.2219

Duration of CD (ref = < 2 years)

≥ 2 years

0.45 (0.17, 1.16)

-

0.0961

Prior CD-related surgery (ref = No)

Yes

0.76 (0.37, 1.58)

-

0.4664

Multivariate regression model

Weight (ref = < 60 kg)

60–74 kg

0.28 (0.09–0.91)

0.0338

 

> 74 kg

0.63 (0.21–1.87)

0.4044

Number of prior biologics received (ref = 0)

1

0.39 (0.15–1.03)

0.0570

 

> 1

1.01 (0.27–3.71)

0.9925

  1. AP = abdominal pain; BUD = budesonide; CD = Crohn’s disease; CI = confidence interval; LSF = loose stool frequency; ref = reference group; VDZ = vedolizumab